Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429021 · ClinicalTrials.gov registry record · Phase 1
IMM-BCP-01 in Mild to Moderate COVID-19
A Phase 1 study, sponsored by Immunome.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05429021 is a Phase 1 study that was terminated before completion, run by Immunome. The registered enrollment target is 9 participants.
The verdict
NCT05429021, a Phase 1 study, was terminated before completion, sponsored by Immunome.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: * Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. * Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Week 12.
Interventions
- DRUG Placebo
- DRUG IMM-BCP-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2023-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05429021
The ClinicalTrials.gov registry entry for NCT05429021 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05429021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05429021 about?
NCT05429021 is a clinical study titled "IMM-BCP-01 in Mild to Moderate COVID-19". The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: * Determine pharmacokinetics (PK) and evaluate viral clearance after single ascendi...
What is the current status of trial NCT05429021?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-06-03. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT05429021?
The interventions under investigation include: Placebo (DRUG), IMM-BCP-01 (DRUG).
Who is sponsoring clinical trial NCT05429021?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.